Stabilized recombinant expression plasmid vector in hafnia alvei and applications thereof

This application claims the benefit of U.S. Provisional Patent Application No. 61/649,719, filed May 21, 2012, which is incorporated by reference as if fully set forth herein.

Cadaverine is a platform chemical involved in the production of various products. Bio-based production of cadaverine has gained research interest since the 1980s. Cadaverine can be synthesized via decarboxylation of lysine in microorganisms. Currently, biosynthesis of cadaverine is performed using two strategies: fermentative production or in vitro enzyme catalysis.

In a fermentative production of L-lysine approach, a lysine decarboxylase gene is added to a lysine producing bacteria strain (e.g. Corynebacterium glutamicum and Escherichia coli ( E. coli )) to extend the lysine biosynthesis pathway to a cadaverine biosynthesis pathway. However, the reported cadaverine yield is lower than the lysine yield for other Corynebacterium glutamicum strains lacking the lysine decarboxylase gene. Such low yield may be due to the toxicity of the cadaverine product to the producing bacterial strain.

Alternatively, bacteria can be engineered or induced to produce lysine decarboxylase for the in vitro enzyme catalysis. One strategy involves inducing expression of a chromosomally encoded lysine decarboxylase gene in an un-engineered Hafnia alvei ( H. alvei ) strain. However, the reported yield of the enzyme is low. Another strategy involves engineering recombinant strains. For example, Japanese companies (JP2009028045, U.S. Pat. No. 7,189,543, CN102056889) have reported the construction of E. coli recombinant strains that over-express lysine decarboxylase and utilize either whole cell or cell lysate for catalysis. However, expression of large amounts of polypeptides that are toxic to the host cell causes expression plasmid instability over serial passage. Antibiotics are required in the medium to ensure plasmid stability during the culture.

Use of antibiotics may cause development of antibiotic resistant bacteria, and maintains high levels of antibiotic resistant microorganisms in the environment. See, e.g. Martinez, “Environmental pollution by antibiotics and by antibiotic resistance determinants,” Environmental Pollution (2009), Vol. 157, Issue 11, 2893-2902. However, antibiotic resistant bacteria potentially pose health and/or environmental hazards. Thus, there remains a need for a more effective recombinant plasmid vector that can remain stable through multiple rounds of serial passage without antibiotic selection.

FIG. 1 shows the construction of the pPlac-cadA-abtabi recombinant expression plasmid vector as discussed in Example 1. a) cadA PCR product produced using the E. coli BL21 chromosome as a template; b) plasmid pMD18-T-cadA produced by ligation of the cadA PCR product to the pMD18-T vector, wherein the short lacZ fragment was located 5′ to the cadA gene; c) pPlac-cadA plasmid after deletion of the lacZ fragment; d) abtlabi PCR product with HindIII sites amplified using H. alvei pAlvB as a template, the PCR product was then ligated to a pMD18-T vector containing a HindIII restriction site; and e) pPlac-cadA-abtabi recombinant expression plasmid produced by HindIII digestion and subsequent ligation of fragments from pPlac-cadA and the pMD18-T vector containing the abt/abi fragment.

FIG. 2 shows the two possible constructions of pPlac-cadA-abtabi recombinant expression plasmid (Type I and Type II) produced according to the methods disclosed herein.

FIG. 3 shows recombinant strain JM109/pPlac-cadA colony growth on LB and LB/Amp plates after serial subculturing and serial dilution as discussed in Example 3.

FIG. 4 shows recombinant strain Ha/pPlac-cadA colony growth on LB and LB/Amp plates after serial subculturing and serial dilution as discussed in Example 3.

FIG. 5 shows recombinant strain Ha c /pPlac-cadA-abtabi colony growth on LB and LB/Amp plates after serial subculturing and serial dilution as discussed in Example 3.

FIG. 6 shows stability of plasmid pPlac-cadA in cured H. alvei.

FIG. 7 shows stability of type I pPlac-cadA-abtabi plasmid in cured H. alvei.

The following description provides specific details for a thorough understanding of, and enabling description for, embodiments of the disclosure. However, one skilled in the art will understand that the disclosure may be practiced without these details. In other instances, well-known structures and functions have not been shown or described in detail to avoid unnecessarily obscuring the description of the embodiments of the disclosure.

The abbreviations used for the amino acids, peptides, base sequences, and nucleic acids in the present disclosure are based on the abbreviations specified in the IUPAC-IUB Communication on Biochemical Nomenclature, Eur. J. Biochem., 138: 9 (1984), “Guideline for Preparing Specifications Including Base Sequences and Amino Acid Sequences” (United States Patent and Trademark Office), and those commonly used in this technical field.

A “nucleotide sequence,” “polynucleotide” or “DNA molecule” as contemplated by the current disclosure, may include double strand DNA or single strand DNA (i.e., a sense chain and an antisense chain constituting the double strand DNA), and a fragment thereof. As used herein, “a fragment thereof” means a part of the nucleotide sequence that encodes a peptide which provides substantially the same function as the peptide encoded by the whole nucleotide sequence. For example, a polynucleotide encoding an antitoxin gene expresses a polypeptide that neutralizes a toxin polypeptide. A fragment of the polynucleotide encoding the antitoxin gene expresses a polypeptide that can neutralize the toxin polypeptide, which provides substantially the same function as the polypeptide encoded by the whole sequence of the polynucleotide encoding the antitoxin gene. Similarly, a fragment of a polynucleotide encoding a toxin gene expresses a polypeptide that is toxic to a cell substantially the same as the toxin polypeptide expressed by the whole sequence of the polynucleotide encoding the toxin gene.

Nucleotide sequences, polynucleotides or DNA molecules as used herein are not limited to the functional region, and may include at least one of an expression suppression region, a coding region, a leader sequence, an exon, an intron and an expression cassette (see, e.g. Papadakis et al., “Promoters and Control Elements: Designing Expression Cassettes for Gene Therapy,” Current Gene Therapy (2004), 4, 89-113). Further, examples of nucleotide sequences or polynucleotides may include RNA or DNA. A polypeptide containing a specific amino acid sequence and a polynucleotide containing a specific DNA sequence may include fragments, homologs, derivatives, and mutants of the polynucleotide. Examples of mutants of a nucleotide sequence or polynucleotide (such as mutant DNA), include naturally occurring allelic mutants; artificial mutants; and mutants having deletion, substitution, addition, and/or insertion. It should be understood that such mutants encode polypeptides having substantially the same function as the polypeptide encoded by the original non-mutated polynucleotide.

One aspect of the invention relates to a stabilized recombinant expression plasmid vector comprising:

a polynucleotide encoding an antitoxin gene which expresses a polypeptide that neutralizes a polypeptide toxic to a host cell, the toxic polypeptide being expressed by a polynucleotide encoding a toxin gene in the host cell,

a polynucleotide encoding a polypeptide expression product, wherein

the stabilized recombinant expression plasmid vector is derived from an autonomously replicable backbone plasmid of a host cell.

In certain embodiments, the toxin gene is chromosomally encoded in the genome of the host cell.

In certain embodiments, the stabilized recombinant expression plasmid vector further comprises the polynucleotide encoding the toxin gene.

In certain embodiments, the polynucleotide encoding the toxin gene and/or the polynucleotide encoding the antitoxin gene is recombinant.

In certain embodiments, one or more genes of the toxin gene, antitoxin gene and polypeptide expression product gene are further optimized using codon optimization technology to provide better expression of the corresponding polypeptides in the host cell. For example, an optimized toxin gene may comprise a DNA sequence optimized to provide a better expression of the toxin polypeptide compared to SEQ ID NO:1 or SEQ ID NO:3. In certain embodiments, the antitoxin gene comprises a DNA sequence further optimized to provide a better expression of the antitoxin polypeptide compared to SEQ ID NO:2 or SEQ ID NO:4. In certain embodiments, the polypeptide expression product gene comprises a DNA sequence further optimized to provide a better expression of the polypeptide expression product compared to SEQ ID NO:5 or SEQ ID NO:6.

Codon optimization is a technique to maximize the protein expression in a host cell by increasing the translational efficiency of gene of interest. DNA sequence of nucleotides of one species is optimized into DNA sequence of nucleotides of another species. A DNA sequence is broken into triplets (codons). The codons of low frequency of an amino acid are replaced with codons for the same amino acid but of high frequency in the host cell. Accordingly, the expression of the optimized DNA sequence is improved in the host cell. See, e.g. www.guptalab.org/shubhg/pdf/shubhra_codon.pdf for an overview of codon optimization technology, which is incorporated herein by reference in its entirety.

As used herein, a toxin/antitoxin gene pair has two genes, one is a toxin gene which expresses a polypeptide toxic to a host cell, and the other is an antitoxin gene which expresses a polypeptide that neutralizes the toxic polypeptide in the host cell.

Certain prokaryotes have one or more chromosomally encoded toxin genes. Certain prokaryotes contain endogenous plasmids that encode specific toxin/antitoxin gene pairs that play a role in maintenance of the genetic information and response to stress. (See, Wertz et al. “Chimeric nature of two plasmids of Hafnia alvei encoding the bacteriocins alveicins A and B.” Journal of Bacteriology, (2004) 186: 1598-1605.) In either case, as long as the cell has one or more plasmids comprising antitoxin gene, the toxin is neutralized by the antitoxin that is continuously expressed by one or more plasmids to keep the cells alive. In certain prokaryotes, the antitoxin protein degrades faster than the toxin protein. If the plasmid comprising the antitoxin gene is lost from the cell, the toxin protein will exist longer than the antitoxin protein in the cell and kill or inhibit the growth of the cell. Therefore, plasmid comprising the antitoxin or the toxin/antitoxin gene is preferably maintained to keep the host cell alive.

Examples of the toxin/antitoxin gene pair include, without limitation, abt/abi gene pair and aat/aai gene pair, and fragments thereof. In certain embodiments, the toxin gene comprises a DNA sequence of SEQ ID NO:1, or SEQ ID NO:3. In certain embodiments, the antitoxin gene comprises a DNA sequence of SEQ ID NO:2, or SEQ ID NO:4.

As used herein, the term “host cell” means a microorganism cell that can be transformed with a stabilized recombinant express plasmid vector. An example of a host cell includes, without limitation, Hafnia alvei ( H. alvei ).

In certain embodiments, the host cell is free of endogenous plasmid either in its native form or by removing any endogenous plasmid. The term “cure” as used herein means to remove endogenous plasmid from the host cell. The resulting endogenous plasmid-free host cell is referred to as a “cured” host cell.

In certain embodiments, the host cell may be selected from any of the H. alvei strains, for example, endogenous plasmid-free H. alvei strains, H. alvei strains having pAlvA plasmids and the cured strains thereof (pAlvA − strains), and H. alvei strains having pAlvB plasmids and the cured strains thereof (pAlvB − strains).

In certain embodiments, the host cell is an industrial strain suitable to be used in industrial-scale or large-scale production. For example, industrial strains may be cultivated in a fermenter. The scale of culture may range from hundreds of liters to millions of liters. On the contrary, a laboratory strain usually is cultivated in a few liters or less. In certain embodiments, an industrial strain may grow in a simpler or more economical medium than laboratory strains.

A polypeptide expression product is a polypeptide produced by a host cell. Examples of polypeptide expression products include, without limitation, any polypeptide expression product that can be produced by E. coli ., e.g. enzymes such as decarboxylases, hydrolases, and phosphorylase. In one embodiment, the decarboxylase is amino acid decarboxylase, e.g. lysine decarboxylase, tyrosine decarboxylase, arginine decarboxylase, ornithine decarboxylase, and glutamate decarboxylase. In another embodiment, a polynucleotide encoding a lysine decarboxylase comprises a haldc gene, a cadA gene, or a fragment thereof. In another embodiment, the polynucleotide encoding a lysine decarboxylase comprises a DNA sequence of SEQ ID NO:5, or SEQ ID NO:6. In another embodiment, the hydrolase is a N-glycosidase or a O-glycosidase, examples include, without limitation, glucosidase, α-glucosidase, β-glucosidase, mannosidase, α-mannosidase, β-mannosidase, fructosidase, β-fructosidase, xylosidase, α-xylosidase, β-xylosidase, galactosidase, α-galactosidase, β-galactosidase, lactase, amylase, α-amylase, β-amylase, myrosinase, chitinase, sucrase, maltase, invertase, hyaluronidase, and neuraminidase. In another embodiment, a polynucleotide encoding a β-galactosidase comprises lacZ gene or a fragment thereof.

An autonomously replicable backbone plasmid of a host cell may be any plasmid that can replicate in the host cell. In one embodiment, the stabilized recombinant plasmid is derived from a backbone plasmid that can replicate in H. alvei . Examples of the backbone plasmids include, without limitation, backbone plasmids that can replicate in E. coli . strains, e.g. pUC (e.g. pUC18 and pUC19 plasmids), pBR322 and pACYC plasmids, and plasmids derived therefrom.

As used herein, a recombinant plasmid “derived from an autonomously replicable backbone plasmid of a host cell” means the recombinant plasmid is constructed by inserting one or more polynucleotides encoding an antitoxin gene, one or more polynucleotides encoding a toxin gene, and/or one or more polynucleotides encoding a polypeptide expression product described herein, and any combination thereof, into the autonomously replicable backbone plasmid of the host cell.

Another aspect of the present disclosure relates to a transformant obtained by transforming one or more stabilized recombinant plasmid vector disclosed herein into a host cell.

As used herein, a transformant is a host cell that has been altered by introducing one or more recombinant plasmid vectors in the host cell. In certain embodiments, the transformant is obtained by introducing a recombinant plasmid vector through transformation into a host cell displaying competence to the plasmid vector.

An antitoxin gene transformant or toxin/antitoxin gene pair transformant shows improved plasmid stability compared to the same host cell transformed by a recombinant plasmid vector that does not contain an antitoxin gene or a toxin/antitoxin gene pair.

In one embodiment, the host cell is an endogenous plasmid-free H. alvei strain. The endogenous plasmid-free H. alvei strain in its native form may be plasmid-free. Alternatively, the endogenous plasmid-free H. alvei strain is a cured H. alvei strain as described supra. The stabilized recombinant plasmid vector comprises one or more antitoxin genes selected from the group consisting of abi gene, aai gene and fragments thereof, and/or one or more toxin/antitoxin gene pairs selected from the group consisting of abt/abi gene pair and aat/aai gene pair, and fragments thereof.

Another aspect of the present disclosure relates to a method of producing cadaverine comprising:

1a) cultivating a transformant comprising a stabilized recombinant expression plasmid vector disclosed herein;

1b) producing cadaverine using the culture obtained from step 1a to decarboxylate lysine; and

1c) recovering cadaverine from the reaction obtained from step 1b.

As used herein, “using the culture obtained from step 1a” may comprise further processes of the culture obtained from step 1a. For example, using a buffer solution to dilute the culture; centrifuging the culture to collect the cells; resuspending the cells in a buffer solution; or lysing the cells into cell lysate; or/and purifying lysine decarboxylase from the cell lysate.

The transformant may be cultured using a medium containing carbon sources and non-carbon nutrient sources. Examples of carbon sources include, without limitation, sugar (e.g. carbohydrates such as glucose and fructose), oil and/or fat, fatty acid, and/or derivatives thereof. The oil and fat may contain saturated and/or unsaturated fatty acids having 10 or more carbon atoms, e.g. coconut oil, palm oil, palm kernel oil, and the like. The fatty acid may be a saturated and/or unsaturated fatty acid, e.g. hexanoic acid, octanoic acid, decanoic acid, lauric acid, oleic acid, palmitic acid, linoleic acid, linolenic acid, myristic acid, and the like. Examples of derivatives of a fatty acid include, without limitation, esters and salts thereof. Examples of non-carbon sources include, without limitation, nitrogen sources, inorganic salts, and other organic nutrient sources.

For example, a medium may contain a carbon source assimilable by the transformant, optionally with one or more other source selected from the group consisting of a nitrogen source, an inorganic salt and another organic nutrient source. In certain embodiments, the weight percentage of the nitrogen source is about 0.01 to 0.1% of the medium. Examples of the nitrogen source may comprise ammonia, ammonium salts (e.g. ammonium chloride, ammonium sulfate and ammonium phosphate), peptone, meat extract, yeast extract, and the like. Examples of the inorganic salts include, without limitation, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, magnesium phosphate, magnesium sulfate, sodium chloride, and the like. Examples of the other organic nutrient source include, without limitation, amino acids (e.g. glycine, alanine, serine, threonine and proline), vitamins (e.g. vitamin B1, vitamin B12 and vitamin C), and the like.

The culture may be carried out at any temperature as long as the cells can grow, and preferably at about 20 to about 40° C., or about 35° C. The culture period may be about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, or about 10 days.

In one embodiment, the transformant is cultured in a medium containing peptides, peptones, vitamins (e.g. B vitamins), trace elements (e.g. nitrogen, sulfur, magnesium), and minerals. Examples of such medium include, without limitation, commonly known Lysogeny broth (LB) mediums comprising tryptone, yeast extract and NaCl suspended in water (e.g. distilled or deionized).

In another embodiment, step 1c of the method further comprises the following steps:

1d) separating the solid and liquid components of the reaction obtained from step 1b;

1e) adjusting the pH of the liquid component obtained from step 1d to about 14 or higher;

1f) removing water from the liquid component obtained from step 1e; and

1g) recovering cadaverine.

In step 1d, the separation of the solid and liquid components of the reaction of step 1b may be accomplished by conventional centrifugation and/or filtration.

In step 1e, the pH of the liquid component of step 1d may be adjusted by adding a base, e.g. NaOH. NaOH may be added as a solid and/or a solution (e.g. an aqueous solution).

In step 1f, the water may be removed by distillation at ambient pressure or under vacuum.

In step 1g, cadaverine may be recovered by distillation at ambient pressure or under vacuum.

Another aspect of the present disclosure relates to biobased cadaverine prepared according to the method disclosed herein.

As used herein, a “biobased” compound means the compound is considered biobased under Standard ASTM D6866.

Another aspect of the present disclosure relates to a polyamide having a structure of Structure 1:

including stereoisomers thereof, wherein:

m=4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22; n=4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22; j=about 100˜about 1,000,000; and the polyamide is prepared from one or more diamines having carbon numbers of m and one or more dicarboxylic acids having carbon numbers of n, at least one of the diamines and dicarboxylic acids comprises biobased carbon under Standard ASTM D6866, and the m or n of each diamine or dicarboxylic acid can be the same or different.

In one embodiment, the diamine is biobased cadaverine, more preferably biobased cadaverine prepared according to the method disclosed herein. Examples of the dicarboxylic acids include, without limitation, C 10 dicarboxylic acid, C 11 dicarboxylic acid, C 12 dicarboxylic acid, C 13 dicarboxylic acid, C 14 dicarboxylic acid, C 16 dicarboxylic acid, C 18 dicarboxylic acid, and any combinations thereof. In certain embodiments, all or part of the C n dicarboxylic acids are biobased.

In another embodiments, the polyamide has a structure described above, wherein:

the polyamide is formed by reacting biobased cadaverine with one or more dicarboxylic acids, more preferably the biobased cadaverine is prepared according to the method disclosed herein. n=4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22; j=about 100˜about 1,000,000, about 1000˜about 100,000, or about 1000˜about 10,000; and the dicarboxylic acids comprise biobased carbon under Standard ASTM D6866.

Another aspect of the present disclosure relates to a method of making the polyamides disclosed herein comprising

preparing biobased cadaverine as the C m diamine according to the method disclosed herein.

In one embodiment, the method further comprises preparing one or more biobased C n dicarboxylic acids.

In another embodiment, the method further comprises preparing the polyamide by reacting biobased cadaverine with one or more biobased C n dicarboxylic acids.

Another aspect of the present disclosure relates to a composition comprising one or more polyamides disclosed herein.

In one embodiment, the diamine is biobased cadaverine, more preferably biobased cadaverine prepared according to the method disclosed herein. Examples of the dicarboxylic acids include, without limitation, C 10 dicarboxylic acid, C 11 dicarboxylic acid, C 12 dicarboxylic acid, C 13 dicarboxylic acid, C 14 dicarboxylic acid, C 16 dicarboxylic acid, C 18 dicarboxylic acid, and any combinations thereof. In certain embodiments, all or part of the C n dicarboxylic acids are biobased.

In another embodiments, the polyamide has a structure described above, wherein:

the polyamide is formed by reacting biobased cadaverine with one or more dicarboxylic acids, more preferably the biobased cadaverine is prepared according to the method disclosed herein. n=4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22; j=about 100˜about 1,000,000, about 1000˜about 100,000, or about 1000˜about 10,000; and the dicarboxylic acids comprise biobased carbon under Standard ASTM D6866.

Another aspect of the present disclosure relates to a method of preparing 1,5-diisocyanatopentane comprising:

2a) preparing biobased cadaverine as disclosed herein; and

2b) converting biobased cadaverine obtained from step 2a to 1,5-diisocyanatopentane.

Step 2b may comprise using any known method to convert diamine into isocyanate. An example of said method is the traditional phosgene method, which includes one-step high temperature phosgene method (i.e. mixing phosgene with diamine at high temperature to obtain isocyanate), the improved two-step phosgene method, and the triphosgene method in which triphosgene is used instead of phosgene. There are also other methods that do not use phosgene as a raw material. An example of said method is hexanediamine carbonylation which uses CO 2 instead of phosgene: CO 2 is added into a solution of a primary amine and an organic base, then a proper amount of phosphorus electrophilic reagents is added into the reaction solution to start an exothermic dehydration reaction to obtain isocyanate. Another example is carbamate thermal decomposition method wherein a primary amine is converted to a carbamate, and then the carbamate is heated to decompose and generate isocyanate.

The following examples are intended to illustrate various embodiments of the invention. As such, the specific embodiments discussed are not to be construed as limitations on the scope of the invention. It will be apparent to one skilled in the art that various equivalents, changes, and modifications may be made without departing from the scope of invention, and it is understood that such equivalent embodiments are to be included herein. Further, all references cited in the disclosure are hereby incorporated by reference in their entireties, as if fully set forth herein.

SEQ ID: NO 1 (aat gene)

>gb|AY271828.1|:385-1717  Hafnia alvei  plasmid pAlvA, complete sequence

1 ttgactttgt taaaagtcag gcataagatc aaaatactgt atatataaca atgtatttat

61 atacagtatt ttatactttt tatctaacgt cagagagggc aatattatga gtggtggaga

121 tggcaagggt cacaatagtg gagcacatga ttccggtggc agcattaatg gaacttctgg

181 gaaaggtggg ccatcaagcg gaggagcatc agataattct gggtggagtt cggaaaataa

241 cccgtggggc ggtggtaact cgggaatgat tggtggcagt caaggaggta acggagctaa

301 tcatggtggc gaaaatacat cttctaacta tgggaaagat gtatcacgcc aaatcggtga

361 tgcgatagcc agaaaggaag gcatcaatcc gaaaatattc actgggtact ttatccgttc

421 agatggatat ttgatcggaa taacgccact tgtcagtggt gatgcctttg gcgttaatct

481 tggcctgttc aataacaatc aaaatagtag tagtgaaaat aagggatgga atggaaggaa

541 tggagatggc attaaaaata gtagccaagg tggatggaag attaaaacta atgaacttac

601 ttcaaaccaa gtagctgctg ctaaatccgt tccagaacct aaaaatagta aatattataa

661 gtccatgaga gaagctagcg atgaggttat taattctaat ttaaaccaag ggcatggagt

721 tggtgaggca gctagagctg aaagagatta cagagaaaaa gtaaagaacg caatcaatga

781 taatagtccc aatgtgctac aggatgctat taaatttaca gcagattttt ataaggaagt

841 ttttaacgct tacggagaaa aagccgaaaa actagccaag ttattagctg atcaagctaa

901 aggtaaaaag atccgcaatg tagaagatgc attgaaatct tatgaaaaac acaaggctaa

961 cattaacaaa aaaatcaatg cgaaagatcg cgaagctatc gccaaggctt tggagtctat

1021 ggatgtagaa aaagccgcaa aaaatatatc caagttcagc aaaggactag gttgggttgg

1081 cccagctatc gatataactg attggtttac agaattatac aaagcagtga aaactgataa

1141 ttggagatct ctttatgtta aaactgaaac tattgcagta gggctagctg caacccatgt

1201 caccgcctta gcattcagtg ctgtcttggg tgggcctata ggtattttag gttatggttt

1261 gattatggct ggggttgggg cgttagttaa cgagacaata gttgacgagg caaataaggt

1321 cattgggatt taa

SEQ ID: NO 2 (aai gene)

>gb|AY271828.1|:1734-2069  Hafnia alvei  plasmid pAlvA, complete sequence

1 ctatatttta gcggtcacat tttttatttc aaaacaaaca gaaagaacac caataggaat

61 tgatgtcata aaaataaaaa taaaatacaa agtcattaaa tatgtttttg gcacaccatc

121 cttaaaaaaa cctgttttcc aaaattcttt tttcgtatat ctaagcgctg ctttctctat

181 tagaaaccga gagaaaggaa atagaatagc gctagccaaa ccaaagattc tgagcgcaat

241 tattttaggt tcgtcatcac cataactggc gtaaagaata caagcagcca taaagtatcc

301 ccaaaacata ttatgtatgt aatatttcct tgtcat

SEQ ID: NO 3 (abt gene)

>gb|AY271829.1|:384-1566  Hafnia   alvei  plasmid pAlvB, complete sequence

1 atgagtggtg gagacggtaa aggtcacaat agtggagcac atgattccgg tggcagcatt

61 aatggaactt cggggaaagg tggacctgat tctggtggcg gatattggga caaccatcca

121 catattacaa tcaccggtgg acgggaagta ggtcaagggg gagctggtat caactggggt

181 ggtggttctg gtcatggtaa cggcgggggc tcagttgcca tccaagaata taacacgagt

241 aaatatccta acacgggagg atttcctcct cttggagacg ctagctggct gttaaatcct

301 ccaaaatggt cggttattga agtaaaatca gaaaactcag catggcgctc ttatattact

361 catgttcaag gtcatgttta caaattgact tttgatggta cgggtaagct cattgatacc

421 gcgtatgtta attatgaacc cagtgatgat actcgttgga gcccgcttaa aagttttaaa

481 tataataaag gaaccgctga aaaacaggtt agggatgcca ttaacaatga aaaagaagca

541 gttaaggacg ctgttaaatt tactgcagac ttctataaag aggtttttaa ggtttacgga

601 gaaaaagccg agaagctcgc taagttatta gcagatcaag ctaaaggcaa aaaggttcgc

661 aacgtagaag atgccttgaa atcttatgaa aaatataaga ctaacattaa caaaaaaatc

721 aatgcgaaag atcgcgaagc tattgctaaa gccttggagt ctatggatgt aggaaaagcc

781 gcaaaaaata tagccaagtt cagtaaagga ctaggttggg ttggccctgc tatcgatata

841 actgattggt ttacagaatt atacaaggca gtggaaactg ataattggag atctttttat

901 gttaaaactg aaactattgc agtagggcta gctgcaaccc atgttgccgc cttggcattc

961 agcgctgtct tgggtgggcc tgtaggtatt ttgggttatg gtttgattat ggctggggtt

1021 ggggcgttag ttaatgagac aatagttgac gaggcaaata aggttattgg gctttaa

SEQ ID: NO 4 (abi gene)

>gb|AY271829.1|:1583-1918  Hafnia alvei  plasmid pAlvB, complete sequence

1 ctataattta gcggtcacat tttttatttc aaaaaaaaca gaaataacac ctataggaat

61 tgatgtcata aaaataaaaa ttaaatacaa agtcattaaa tatgtttttg gcacgccatc

121 cttaaaaaaa ccagtttccc aaaattcttt tttcgtatat ctaagcgcgg ttttctctat

181 taaaaaccga gagaaaggga ataggatagc actagccaaa ccaaagattc tgagcgcaat

241 tattttaggt tcgttatccc cataactggc gtaaagaata caaacagcca taaagtaccc

301 ccaaaacata ttatgtatat aatatttcct tgtcat

SEQ ID: NO 5 ( E. coli  gene for lysine decarboxylase (cadA))

>gb|M76411.1|ECOCADABC:1913-4060  E.coli  cadA gene, 5′ cds and cadB and cadC

genes, complete cds

1 atgaacgtta ttgcaatatt gaatcacatg ggggtttatt ttaaagaaga acccatccgt

61 gaacttcatc gcgcgcttga acgtctgaac ttccagattg tttacccgaa cgaccgtgac

121 gacttattaa aactgatcga aaacaatgcg cgtctgtgcg gcgttatttt tgactgggat

181 aaatataatc tcgagctgtg cgaagaaatt agcaaaatga acgagaacct gccgttgtac

241 gcgttcgcta atacgtattc cactctcgat gtaagcctga atgacctgcg tttacagatt

301 agcttctttg aatatgcgct gggtgctgct gaagatattg ctaataagat caagcagacc

361 actgacgaat atatcaacac tattctgcct ccgctgacta aagcactgtt taaatatgtt

421 cgtgaaggta aatatacttt ctgtactcct ggtcacatgg gcggtactgc attccagaaa

481 agcccggtag gtagcctgtt ctatgatttc tttggtccga ataccatgaa atctgatatt

541 tccatttcag tatctgaact gggttctctg ctggatcaca gtggtccaca caaagaagca

601 gaacagtata tcgctcgcgt ctttaacgca gaccgcagct acatggtgac caacggtact

661 tccactgcga acaaaattgt tggtatgtac tctgctccag caggcagcac cattctgatt

721 gaccgtaact gccacaaatc gctgacccac ctgatgatga tgagcgatgt tacgccaatc

781 tatttccgcc cgacccgtaa cgcttacggt attcttggtg gtatcccaca gagtgaattc

841 cagcacgcta ccattgctaa gcgcgtgaaa gaaacaccaa acgcaacctg gccggtacat

901 gctgtaatta ccaactctac ctatgatggt ctgctgtaca acaccgactt catcaagaaa

961 acactggatg tgaaatccat ccactttgac tccgcgtggg tgccttacac caacttctca

1021 ccgatttacg aaggtaaatg cggtatgagc ggtggccgtg tagaagggaa agtgatttac

1081 gaaacccagt ccactcacaa actgctggcg gcgttctctc aggcttccat gatccacgtt

1141 aaaggtgacg taaacgaaga aacctttaac gaagcctaca tgatgcacac caccacttct

1201 ccgcactacg gtatcgtggc gtccactgaa accgctgcgg cgatgatgaa aggcaatgca

1261 ggtaagcgtc tgatcaacgg ttctattgaa cgtgcgatca aattccgtaa agagatcaaa

1321 cgtctgagaa cggaatctga tggctggttc tttgatgtat ggcagccgga tcatatcgat

1381 acgactgaat gctggccgct gcgttctgac agcacctggc acggcttcaa aaacatcgat

1441 aacgagcaca tgtatcttga cccgatcaaa gtcaccctgc tgactccggg gatggaaaaa

1501 gacggcacca tgagcgactt tggtattccg gccagcatcg tggcgaaata cctcgacgaa

1561 catggcatcg ttgttgagaa aaccggtccg tataacctgc tgttcctgtt cagcatcggt

1621 atcgataaga ccaaagcact gagcctgctg cgtgctctga ctgactttaa acgtgcgttc

1681 gacctgaacc tgcgtgtgaa aaacatgctg ccgtctctgt atcgtgaaga tcctgaattc

1741 tatgaaaaca tgcgtattca ggaactggct cagaatatcc acaaactgat tgttcaccac

1801 aatctgccgg atctgatgta tcgcgcattt gaagtgctgc cgacgatggt aatgactccg

1861 tatgctgcat tccagaaaga gctgcacggt atgaccgaag aagtttacct cgacgaaatg

1921 gtaggtcgta ttaacgccaa tatgatcctt ccgtacccgc cgggagttcc tctggtaatg

1981 ccgggtgaaa tgatcaccga agaaagccgt ccggttctgg agttcctgca gatgctgtgt

2041 gaaatcggcg ctcactatcc gggctttgaa accgatattc acggtgcata ccgtcaggct

2101 gatggccgct ataccgttaa ggtattgaaa gaagaaagca aaaaataa

SEQ ID: NO 6 ( Hafnia Alvei  gene for lysine decarboxylase (haldc)

>gi|43438|emb|X03774.1| Hafnia alvei  gene for lysine decarboxylase (LDC)

1 atgaatatca ttgccatcat gaacgattta agcgcttatt ttaaggaaga acccctgcgc

61 gagctgcatc aagagttaga gaaggaaggc ttccgtattg cttatcccaa agaccgcaac

121 gatctgctga agctgattga aaacaactcc cgcctgtgtg gcgtcatttt cgactgggat

181 aaatataacc tcgaactcag cgctgaaatc agcgagctca acaaactgct gccaatttat

241 gccttcgcca atacctattc gacgcttgac gtcaacatga gcgacctgcg tcttaatgtt

301 cgcttctttg aatatgcatt aggcagcgcg caagacattg ccaccaagat ccgccaaagc

361 accgatcagt atattgatac cattctgcca ccgctgacca aggcgctgtt caaatacgtc

421 aaagaagaga aatacacagt ctgtacgccg gggcatatgg gcggaactgc gttcgataaa

481 agccctgtcg gtagcctgtt ctatgatttc ttcggtgaaa acaccatgcg ttcggatatc

541 tcgatctccg tatctgagct cggatcgctg ctcgatcata gcggcccaca ccgtgacgcc

601 gaagagtata tcgcgcgcac gttcaacgcc gatcgcagct atatcgtaac caacggaaca

661 tctacggcga ataaaattgt cggcatgtat tcatctcctg ccggtgccac tattctgata

721 gaccgtaact gccataaatc attgacccat ttgatgatga tgagcaacgt tgtccccgtc

781 tatctgcgcc caacccgtaa cgcctacggc attttaggcg ggataccgca aagcgagttc

841 acccgcgcca gcattgaaga gaaagtgaaa aatacgccca atgcgacatg gccggtgcat

901 gcggtagtca ccaactctac ctatgacggc ctgttctaca ataccgaata catcaaaaac

961 acgcttgatg ttaagtcgat tcacttcgat tcggcatggg tgccttacac caacttccat

1021 ccgatttacc aaggcaaagc agggatgagc ggtgaacgtg tgccggggaa aatcatctac

1081 gagactcagt ccacccacaa actgctggcg gcattctcgc aggcatcgat gatccacgtg

1141 aaaggtgaga tcaacgaaga aaccttcaat gaagcctata tgatgcatac ctcaacatca

1201 ccgcattacg ggatcgttgc gtcgacggaa accgcggcgg ctatgatgaa gggcaacgcc

1261 ggtaagcgtt taattaacgg ttcaattgaa cgagcgatcc gcttccgtaa agagatccgc

1321 cgcttacgta cagaatctga tggctggttc tttgacgtat ggcagccgga taacattgac

1381 gaggttgctt gctggccact caatccacgt aatgaatggc atggattccc gaacatcgac

1441 aacgatcata tgtatcttga tccgatcaaa gtcactctgc tgaccccagg tttaagcccc

1501 aatggcactc tggaagagga agggataccg gcgtcgatcg tgtcgaaata tctggatgag

1561 cacggcatca tcgtggaaaa aaccgggcca tataacctgc tcttcctgtt tagtatcggg

1621 atcgataaaa ccaaggcgtt gagcttgttg cgggcattaa ccgatttcaa acgcgtgtat

1681 gacctcaacc tgcgcgtgaa aaacgtgttg ccatcgctct ataacgaggc gcctgatttc

1741 tataaagaga tgcgaattca ggagttggct caggggattc atgctctggt gaaacaccac

1801 aatctaccag acctgatgta tcgtgcattt gaggtattac caaagctggt gatgacgccg

1861 catgatgcgt tccaagaaga agtgcgtggc aatattgagc catgtgcctt ggatgatatg

1921 ttagggaaag ttagcgccaa catgatcttg ccgtatcctc cgggtgttcc ggtggttatg

1981 ccgggagaaa tgctcactaa ggagagccgc cctgttctga gcttcttgca gatgctatgt

2041 gaaattggcg cacactatcc gggctttgaa acggatattc acggcgttca tcgtgatggt

2101 gcaacgggta aatacatggt cgtggtgctc aaacaaggcg cagatgaacc gggtgataaa

2161 ccgagtgata cggtgaagaa agcgccgggt aaaaaaccat cagcggcgaa gaagtcataa

SEQ ID: NO 7

1 ATGAACGTTA TTGCAATATT

SEQ ID: NO 8

1 ACTGAAAGCT TCCACTTCCC TTGTACGAGC T

SEQ ID: NO 9

1 ATTCAATATT GCAATAACGT TCATAGCTGT TTCCTGTGTG

SEQ ID: NO 10

1 AGGAAACAGC TATGAACGTT

SEQ ID: NO 11

1 ACTGAAAGCTT TACTTTCATC ACAAGCCTCT

SEQ ID: NO 12

1 ACTGAAAGCTT AGATTCAGCG CGAGAGTGAT

SEQ ID: NO 13

1 ACTGAAAGCT TTTTAATTGT GTGACCACTA T